← Back to Clinical Trials
Recruiting NCT07451899

NCT07451899 TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07451899
Status Recruiting
Phase
Sponsor Universitas Padjadjaran
Condition Post Tuberculosis
Study Type OBSERVATIONAL
Enrollment 20 participants
Start Date 2026-03-01
Primary Completion 2026-05-31

Eligibility & Interventions

Sex All sexes
Min Age 10 Years
Max Age 18 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20 participants in total. It began in 2026-03-01 with a primary completion date of 2026-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Post-Tuberculosis Lung Disease (PTLD) is defined as chronic respiratory impairment due to previous pulmonary TB. Children recovering from pulmonary TB undergo ongoing respiratory health challenges, including more frequent respiratory symptoms, reduced lung volumes, and a threefold higher rate of pulmonary dysfunction compared to healthy children. These conditions could lead to long-term health consequences such as difficulties in performing daily activities. Pulmonary function impairment in PTLD includes approximately 10% of patients losing more than 50% of lung function. Adolescents who have undergone TB treatment often experience pulmonary function impairment and reduced physical capacity. This aims of this study is to analyze the correlation between type of tuberculosis, spirometry result, and functional capacity in adolescents with post-tuberculosis lung disease. This study is an analytical observational study with a cross-sectional approach. This study is conducted at Department of Physical Medicine and Rehabilitation, Hasan Sadikin Hospital, Bandung, starting in March until May 2026. Inclusion criteria including: adolescents (10-18 year old), and diagnosed with post tuberculosis lung disease by pediatrician, and capable of performing the 6MWT. The participants with post TB lung disease will undergo spirometry and functional capacity assessment using the 6-minute walk test (6MWT). Outcomes include spirometry result and functional capacity using 6MWT.

Eligibility Criteria

Inclusion Criteria: * Adolescents (10-18 year old) * Diagnosed with post tuberculosis lung disease by pediatrician * Capable of performing the 6MWT Exclusion Criteria: * Diagnosed with another lung disease * Having physical limitations that hinder the 6MWT

Contact & Investigator

Central Contact

Irma R Defi, MD, PhD

✉ irmaruslina@gmail.com

📞 +6216908139

Principal Investigator

Irma R Defi, MD, PhD

PRINCIPAL INVESTIGATOR

Hasan Sadikin General Hospital

Frequently Asked Questions

Who can join the NCT07451899 clinical trial?

This trial is open to participants of all sexes, aged 10 Years or older, up to 18 Years, studying Post Tuberculosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07451899 currently recruiting?

Yes, NCT07451899 is actively recruiting participants. Contact the research team at irmaruslina@gmail.com for enrollment information.

Where is the NCT07451899 trial being conducted?

This trial is being conducted at Bandung, Indonesia.

Who is sponsoring the NCT07451899 clinical trial?

NCT07451899 is sponsored by Universitas Padjadjaran. The principal investigator is Irma R Defi, MD, PhD at Hasan Sadikin General Hospital. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology